Sonus and Abbott re-negotiate marketing deal
This article was originally published in Clinica
Abbott is to cut back royalty payments to Sonus Pharmaceuticals for international sales of Sonus' second-generation ultrasound contrast imaging agent, EchoGen. The move is part of an amendment to the two companies' marketing and distribution agreement for the product, which is pending US approval.
You may also be interested in...
Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
At the OurCrowd Global Investor Summit in Jerusalem, Israel, on 13 February, Medtech Insight met wound care device company Nanomedic to find out more about its unique electro-spinning technology.